Literature DB >> 19789344

Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.

Sarmishtha De1, Rocky Cipriano, Mark W Jackson, George R Stark.   

Abstract

Resistance to chemotherapy remains a major barrier to the successful treatment of cancer. To understand mechanisms underlying docetaxel resistance in breast cancer, we used an insertional mutagenesis strategy to identify proteins whose overexpression confers resistance. A strong promoter was inserted approximately randomly into the genomes of tumor-derived breast cancer cells, using a novel lentiviral vector. We isolated a docetaxel-resistant clone in which the level of the kinesin KIFC3 was elevated. When KIFC3 or the additional kinesins KIFC1, KIF1A, or KIF5A were overexpressed in the breast cancer cell lines MDA-MB231 and MDA-MB 468, the cells became more resistant to docetaxel. The binding of kinesins to microtubules opposes the stabilizing effect of docetaxel that prevents cytokinesis and leads to apoptosis. Our finding that kinesins can mediate docetaxel resistance might lead to novel therapeutic approaches in which kinesin inhibitors are paired with taxanes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789344     DOI: 10.1158/0008-5472.CAN-09-1224

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

1.  FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB.

Authors:  Canhui Guo; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

Authors:  Ekaterina V Kalashnikova; Alexey S Revenko; Abigael T Gemo; Nicolas P Andrews; Clifford G Tepper; June X Zou; Robert D Cardiff; Alexander D Borowsky; Hong-Wu Chen
Journal:  Cancer Res       Date:  2010-09-23       Impact factor: 12.701

3.  KIFC1 is a novel potential therapeutic target for breast cancer.

Authors:  Yonghe Li; Wenyan Lu; Dongquan Chen; Rebecca J Boohaker; Ling Zhai; Indira Padmalayam; Krister Wennerberg; Bo Xu; Wei Zhang
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

4.  The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma.

Authors:  Joseph R McCorkle; Mary K Leonard; Susan D Kraner; Eric M Blalock; Deqin Ma; Stephen G Zimmer; David M Kaetzel
Journal:  Cancer Genomics Proteomics       Date:  2014 Jul-Aug       Impact factor: 4.069

5.  KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway.

Authors:  Yang Gao; Liangdong Li; Hui Zheng; Changshuai Zhou; Xin Chen; Bin Hao; Yiqun Cao
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

Review 6.  Centrosome clustering and chromosomal (in)stability: a matter of life and death.

Authors:  Alwin Krämer; Bettina Maier; Jiri Bartek
Journal:  Mol Oncol       Date:  2011-05-19       Impact factor: 6.603

Review 7.  Kinesins and cancer.

Authors:  Oliver Rath; Frank Kozielski
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

8.  Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.

Authors:  June X Zou; Zhijian Duan; Junjian Wang; Alex Sokolov; Jianzhen Xu; Christopher Z Chen; Jian Jian Li; Hong-Wu Chen
Journal:  Mol Cancer Res       Date:  2014-01-03       Impact factor: 5.852

9.  The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.

Authors:  Grace Huang; Baotran Ho; Jeffrey Conroy; Song Liu; Hu Qiang; Vita Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

10.  Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.

Authors:  Evan R Zynda; Vitaliy Matveev; Michael Makhanov; Alexander Chenchik; Eugene S Kandel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.